Last edition
News about "FIRDAPSE "
Catalyst Pharmaceuticals Announces Launch of FIRDAPSE in Japan by DyDo
FIRDAPSE (amifampridine) is the only US FDA approved, evidence-based therapy for the treatment of LEMS in adults and pediatric patients six years of age and older.
FIRDAPSE | 22/01/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members